Rustin Walters, MD
Payments from drug & device makers
Across 181 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$864
- Bayer$335
- Merck$322
- Teleflex LLC$280
- Sumitomo Pharma America, Inc.$279
- Dendreon Pharmaceuticals LLC$262
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,27599%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $864 |
| Bayer | 12 | $335 |
| Merck | 15 | $322 |
| Teleflex LLC | 14 | $280 |
| Sumitomo Pharma America, Inc. | 14 | $279 |
| Dendreon Pharmaceuticals LLC | 10 | $262 |
| AstraZeneca | 8 | $228 |
| Pfizer | 9 | $207 |
| Accord Healthcare, Inc. | 9 | $160 |
| Urogen Pharma, Inc. | 7 | $154 |
| Calyxo, Inc. | 1 | $149 |
| Immunitybio, Inc. | 4 | $112 |
| Tolmar, Inc. | 5 | $102 |
| Vertex | 3 | $79 |
| Blue Earth Diagnostics | 4 | $77 |
| Ferring Pharmaceuticals Inc. | 3 | $72 |
| Endo Pharmaceuticals Inc. | 5 | $71 |
| Olympus America Inc. | 3 | $71 |
| Antares Pharma, Inc. | 4 | $64 |
| Novo Nordisk | 3 | $63 |
| Astellas Pharma US Inc | 4 | $62 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Endo USA, Inc. | 2 | $38 |
| Urovant Sciences Inc | 2 | $31 |
| Halozyme Inc | 1 | $29 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Telix Pharmaceuticals | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Coloplast | 1 | $17 |
| Neotract Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,298 in reported general payments places this provider in the 50th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 35 | $32,033 |
| MyrbetriqMirabegron | 45 | $22,568 |
| Testosterone Cypionate | 87 | $4,158 |
| Tamsulosin Hcl | 239 | $3,085 |
| Solifenacin Succinate | 23 | $2,846 |
| Tolterodine Tartrate ErTolterodine Tartrate | 44 | $2,664 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $1,020 |
| Methenamine Hippurate | 24 | $960 |
| Estradiol | 16 | $776 |
| Trospium Chloride | 15 | $643 |
| Finasteride | 29 | $509 |
| Levofloxacin | 61 | $478 |
| Oxybutynin Chloride | 86 | $368 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $338 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 80 | $275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $279 | $32,03335 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $22,56845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 145 urology providers in Oklahoma.
Other urology in Tulsa
- Melanie KetchandjiTulsa$111K
- Curtis PowellTulsa$66K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Charles PritchardTulsa$23K
- Sean DoyleTulsa$17K
- Joshua VicenaTulsa$16K
- Wesley BrookoverTulsa$13K
- Thomas RashidTulsa$12K
- Dae KimTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.